Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05924477 · ClinicalTrials.gov registry record · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
A NA study of Glaucoma, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 226
- Enrollment target
- 8
- Study locations
NCT05924477: Recruiting NA study of Glaucoma, sponsored by University of Pennsylvania.
NCT05924477 is a NA study of Glaucoma that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 226 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05924477, a NA study of Glaucoma, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 226 participants
- Enrollment target
- 8
- Study locations
Study Summary
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.
Primary Outcome
Change in central endothelial cell density based on assessment of Specular Microscopy images.
Conditions Studied
Interventions
- PROCEDURE Sulcus tube placement
- PROCEDURE Anterior chamber (AC) tube placement
Study Locations (8)
California
- University of California San Francisco - San Francisco
- Diablo Eye Associates - Walnut Creek
Florida
- Bascom Palmer Eye Institute - Miami
Maryland
- Wilmer Eye Institute, Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts Eye and Ear - Boston
New York
- University of Buffalo/State University of New York - Buffalo
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Other
- Prism Eye Institute, University of Toronto - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT05924477 shows while recruiting
NCT05924477 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Sulcus tube placement is the first listed.
NCT05924477 lists 8 locations in 7 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT05924477 about?
NCT05924477 is a clinical study titled "Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial". Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris ...
What is the current status of trial NCT05924477?
This trial is currently recruiting. It is a NA study. The enrollment target is 226 participants. The study started on 2023-07-11. Estimated completion is 2027-12.
What conditions does trial NCT05924477 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT05924477?
The interventions under investigation include: Sulcus tube placement (PROCEDURE), Anterior chamber (AC) tube placement (PROCEDURE).
Who is sponsoring clinical trial NCT05924477?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05924477 being conducted?
This trial has 8 study locations across California, Florida, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05924477's enrollment target sits among peer trials
226 25th of 92 higher than 68 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Glaucoma
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT06106945 · 226 participants · Phase 1
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI